Why the study?
Recent advances in immunology, neurobiology, genetics, and triggers of multiple sclerosis have broadened the treatment focus, prompting a summary of these developments.
Advances in multiple sclerosis therapies have significantly improved patient prognosis, allowing most newly diagnosed patients to live without disability.
The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on treatment, adding realistic possibilities for prevention and repair. Here, we summarize recent advances that have together transformed the disease from the most common crippler of young adults in the western world to its place today as a condition in which most newly diagnosed patients can anticipate lives free from disability. ANN NEUROL 2025;98:317-328.
No takes yet. Share an insight, caveat, or question.
Sabatino et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: